May 26, 2020
The US FDA has granted approval for Takeda Pharmaceutical’s ALK inhibitor Alunbrig (brigatinib) as a first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC). The Japanese giant said on May 23 that the US regulator approved Alunbrig for adult...read more